ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency

Journal of Lipid Research

Volumn 49, Issue 5, 2008, Pages 1048-1055

  Gerritsen, Gery ^a   Van Der Hoogt, Caroline C ^a,b   Schaap, Frank G ^c   Voshol, Peter J ^a,b   Kypreos, Kyriakos E ^a,d   Maeda, Nobuyo ^e   Groen, Albert K ^c   Havekes, Louis M ^a,b   Rensen, Patrick C N ^a,b   Van Dijk, Ko Willems ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus mediated gene transfer; APOE2 knockin mice; Apolipoprotein A V; Apolipoprotein C III; Apolipoprotein E2; Lipoprotein lipase mediated very low density lipoprotein triglyceride hydrolysis

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A5; APOLIPOPROTEIN B; APOLIPOPROTEIN C; APOLIPOPROTEIN C3; APOLIPOPROTEIN D; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN M; BETA2 GLYCOPROTEIN 1; CLUSTERIN; HEPARIN; APOA5 PROTEIN, MOUSE; APOLIPOPROTEIN; LIPID; LIPOPROTEIN LIPASE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HYPERTRIGLYCERIDEMIA; IN VIVO STUDY; LIPOPROTEIN DEFICIENCY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STIMULATION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ARTICLE; BLOOD; GENE TRANSFER; GENETICS; MOUSE MUTANT; PHYSIOLOGY;

ADENOVIRIDAE; ANIMALS; APOLIPOPROTEIN C-III; APOLIPOPROTEIN E2; APOLIPOPROTEINS; GENE TRANSFER TECHNIQUES; HYPERTRIGLYCERIDEMIA; LIPIDS; LIPOPROTEIN LIPASE; MALE; MICE; MICE, KNOCKOUT;

EID: 50049105599     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800009-JLR200     Document Type: Conference Paper

References (41)

1. Brewer, H. B.,Jr., L. A. Zech, R. E. Gregg, D. Schwartz, and E.J. Schaefer. 1983. NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann. Intern. Med. 98: 623-640.
2. Schneider, W. J., P. T. Kovanen, M. S. Brown, J. L. Goldstein, G. Utermann, W. Weber, R. J. Havel, L. Kotite, J. P. Kane, T. L. Innerarity, et al. 1981. Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. J. Clin. Invest. 68: 1075-1085.
3. Weisgraber, K. H., T. L. Innerarity, and R. W. Mahley. 1982. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem. 257: 2518-2521.
4. Gregg, R. E., L. A. Zech, E. J. Schaefer, and H. B. Brewer, Jr. 1981. Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E. Science. 211: 584-586.
5. Huang, Y.,X. Q.Liu,S.C.Rall, Jr., andR.W. Mahley. 1998. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins. J. Biol. Chem. 273: 17483-17490.
6. de Man, F. H., F. de Beer, A. van de Laarse, A. H. Smelt, J. A. Leuven, and L. M. Havekes. 1998. Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphate proteoglycan-bound lipoprotein lipase. Atherosclerosis. 136: 255-262.
7. van Dijk, K. W., P. C. Rensen, P.J. Voshol, and L. M. Havekes. 2004. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? Curr. Opin. Lipidol. 15: 239-246.
8. Schaap, F. G., P. C. Rensen, P. J. Voshol, C. Vrins, H. N. van der Vliet, R. A. Chamuleau, L. M. Havekes, A. K. Groen, and K. W. van Dijk. 2004. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein- triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis.J.Biol. Chem. 279: 27941-27947.
9. Merkel, M., and J. Heeren. 2005. Give me A5 for lipoprotein hydrolysis! J. Clin. Invest. 115: 2694-2696.
10. Merkel, M., B. Loeffler, M. Kluger, N. Fabig, G. Geppert, L. A. Pennacchio, A. Laatsch, and J. Heeren. 2005. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan bound lipoprotein lipase. J. Biol. Chem. 280: 21553-21560.
11. Wang, C. S., W.J. McConathy, H. U. Kloer, and P. Alaupovic. 1985. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J. Clin. Invest. 75: 384-390.
12. 12.Ginsberg,H.N.,N.A. Le,I.J.Goldberg,J.C.Gibson, A. Rubinstein, P. Wang-Iverson, R. Norum, and W. V. Brown. 1986. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J. Clin. Invest. 78: 1287-1295.
13. van der Vliet, H. N., F. G. Schaap, J. H. Levels, R. Ottenhoff, N. Looije, J. G. Wesseling, A. K. Groen, and R. A. Chamuleau. 2002. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem. Biophys. Res. Commun. 295: 1156-1159.
14. Ebara, T., R. Ramakrishnan, G. Steiner, and N. S. Shachter. 1997. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hyper-triglyceridemia is not mediated by effects on apolipoprotein E. J. Clin. Invest. 99: 2672-2681.
15. 15.Jong,M.C.,P.C.Rensen,V.E.Dahlmans,H.vanderBoom, T. J. van Berkel, and L. M. Havekes. 2001. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J. Lipid Res. 42: 1578-1585.
16. Gerritsen, G., P. C. Rensen, K. E. Kypreos, V. I. Zannis, L. M. Havekes, and W. van Dijk. 2005. ApoCIII deficiency prevents hyperlipidemia induced by apoE overexpression. J. Lipid Res. 46: 1466-1473.
17. Grosskopf, I., N. Baroukh, S. J. Lee, Y. Kamari, D. Harats, E. M. Rubin, L. A. Pennacchio, and A. D. Cooper. 2005. Apolipoprotein A-V deficiency results in marked hypertriglycer-idemia attributable to decreased lipolysis of triglyceride-rich lipo-proteins and removal of their remnants. Arterioscler. Thromb. Vasc. Biol. 25: 2573-2579.
18. Marcais, C., B. Verges, S. Charriere, V. Pruneta, M. Merlin, S. Billon, L. Perrot, J. Drai, A. Sassolas, L. A. Pennacchio, et al. 2005. Apoa5 Q139X truncation predisposes to late-onset hyperchylo-micronemia due to lipoprotein lipase impairment. J. Clin. Invest. 115: 2862-2869.
19. Oliva, C. P., L. Pisciotta, V. G. Li, M. P. Sambataro, A. Cantafora, A. Bellocchio, A. Catapano, P. Tarugi, S. Bertolini, and S. Calandra. 2005. Inherited apolipoprotein A-V deficiency in severe hypertri-glyceridemia. Arterioscler. Thromb. Vasc. Biol. 25: 411-417.
20. Kobayashi, J., D. Applebaum-Bowden, K. A. Dugi, D. R. Brown, V. S. Kashyap, C. Parrott, C. Duarte, N. Maeda, and S. Santamarina-Fojo. 1996. Analysis of protein structure-function in vivo. Adenovirus-mediated transfer of lipase lid mutants in hepatic lipase-deficient mice. J. Biol. Chem. 271: 26296-26301.
21. van Dijk, K. W., K. E. Kypreos, C. d'Oliveira, and F. J. Fallaux. 2003. Adenovirus-mediated gene transfer. Methods Mol. Biol. 209: 231-247.
22. Sullivan, P. M., H. Mezdour, S. H. Quarfordt, and N. Maeda. 1998. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J. Clin. Invest. 102: 130-135.
23. Tao, N., G. P. Gao, M. Parr, J. Johnston, T. Baradet, J. M. Wilson, J. Barsoum, and S. E. Fawell. 2001. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther. 3: 28-35.
24. van Vlijmen, B. J., H. B. van't Hof, M. J. Mol, H. van der Boom, A. van der Zee, R. R. Frants, M. H. Hofker, and L. M. Havekes. 1996. Modulation of very low density lipoprotein production and clearance contributes to age- and gender-dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice. J. Clin. Invest. 97: 1184-1192.
25. Aalto-Setälä, K., E. A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, A. Walsh, R. Ramakrishnan, H. N. Ginsberg, and J. L. Breslow. 1992. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J. Clin. Invest. 90: 1889-1900.
26. Jong, M. C., V. E. Dahlmans, M. H. Hofker, and L. M. Havekes. 1997. Nascent very-low-density lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-dependent manner. Biochem. J. 328: 745-750.
27. van Dijk, K. W., B. J. van Vlijmen, H. B. van't Hof, A. van der Zee, S. Santamarina-Fojo, T. J. van Berkel, L. M. Havekes, and M. H. Hofker. 1999. In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apoE but is inhibited by excess apoE. J. Lipid Res. 40: 336-344.
28. Rensen, P. C., and T. J. van Berkel. 1996. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo. J. Biol. Chem. 271: 14791-14799.
29. Mahley, R. W., and Z. S. Ji. 1999. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40: 1-16.
30. Ji, Z. S., S. Fazio, and R. W. Mahley. 1994. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J. Biol. Chem. 269: 13421-13428.
31. Lookene, A., J. A. Beckstead, S. Nilsson, G. Olivecrona, and R. O. Ryan. 2005. Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J. Biol. Chem. 280: 25383-25387.
32. van Barlingen, H. H., H. de Jong, D. W. Erkelens, and T. W. de Bruin. 1996. Lipoprotein lipase-enhanced binding of human triglyceride-rich lipoproteins to heparan sulfate: modulation by apolipoprotein E and apolipoprotein C. J. Lipid Res. 37: 754-763.
33. Fruchart-Najib, J., E. Bauge, L. S. Niculescu, T. Pham, B. Thomas, C. Rommens, Z. Majd, B. Brewer, L. A. Pennacchio, and J. C. Fruchart. 2004. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem. Biophys. Res. Commun. 319: 397-404.
34. Dallinga-Thie, G. M., A. van Tol, H. Hattori, L. C. van Vark-van der Zee, H. Jansen, E. J. Sijbrands, and the DALI Study Group. 2006. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia. 49: 1505-1511.
35. Talmud, P. J., J. A. Cooper, H. Hattori, I. P. Miller, G. J. Miller, and S. E. Humphries. 2006. The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II. Diabetologia. 49: 2337-2340.
36. Henneman, P., F. G. Schaap, L. M. Havekes, P. C. Rensen, R. R. Frants, A. van Tol, H. Hattori, A. H. Smelt, and K. W. van Dijk. 2007. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis. 193: 129-134.
37. Pennacchio, L. A., M. Olivier, J. A. Hubacek, R. M. Krauss, E. M. Rubin, andJ. C. Cohen. 2002. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum. Mol. Genet. 11: 3031-3038.
38. Talmud, P. J., J. Palmen, W. Putt, L. Lins, and S. E. Humphries. 2005. Determination of the functionality of common APOA5 polymorphisms. J. Biol. Chem. 280: 28215-28220.
39. Wright, W. T., I. S. Young, D. P. Nicholls, C. Patterson, K. Lyttle, and C. A. Graham. 2006. SNPs at the APOA5 gene account for the strong association with hypertriglyceridaemia at the APOA5/A4/C3/A1 locus on chromosome 11q23 in the Northern Irish population. Atherosclerosis. 185: 353-360.
40. Tang, Y., P. Sun, D. Guo, A. Ferro, Y. Ji, Q. Chen, and L. Fan. 2006. A genetic variant c.553G>T in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and altered triglyceride levels in a Chinese population. Atherosclerosis. 185: 433-437.
41. Hoffer, M. J., E.J. Sijbrands, F. H. de Man, L. M. Havekes, A. H. Smelt, and R. R. Frants. 1998. Increased risk for endogenous hypertriglyceridaemia is associated with an apolipoprotein C3 haplotype specified by the SstI polymorphism. Eur. J. Clin. Invest. 28: 807-812.